2023
DOI: 10.1208/s12248-023-00795-5
|View full text |Cite
|
Sign up to set email alerts
|

Dissolution Profile Similarity Assessment—Best Practices, Decision Trees and Global Harmonization

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
2
0

Year Published

2023
2023
2024
2024

Publication Types

Select...
5

Relationship

0
5

Authors

Journals

citations
Cited by 5 publications
(2 citation statements)
references
References 19 publications
0
2
0
Order By: Relevance
“…Many statistical approaches have been developed to test the similarity between dissolution curves or profiles, including cluster analysis, decision trees, and linear models; see, e.g. Costa and Sousa Lobo (2001), Maggio et al (2008), Enachescu (2010), Paix ao et al (2017), Abend et al (2023), Pourmohamad and Ng (2023). That also includes nonparametric measures such as the two measures adopted by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA),…”
Section: Detecting Similarity Of Drug Dissolution Profilesmentioning
confidence: 99%
“…Many statistical approaches have been developed to test the similarity between dissolution curves or profiles, including cluster analysis, decision trees, and linear models; see, e.g. Costa and Sousa Lobo (2001), Maggio et al (2008), Enachescu (2010), Paix ao et al (2017), Abend et al (2023), Pourmohamad and Ng (2023). That also includes nonparametric measures such as the two measures adopted by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA),…”
Section: Detecting Similarity Of Drug Dissolution Profilesmentioning
confidence: 99%
“…Dissolution testing performed under multiple pH conditions or the approved QC method, which may or may not contain surfactants, is not a priori indicative of unacceptable in vivo performance unless these methods are clinically relevant (21). Once a clinically relevant dissolution method (CRDM) has been developed and validated, this method should be used to assess the impact of manufacturing changes as opposed to any dissolution methods with unknown clinical relevance (22). A clinically relevant dissolution specification (CRDS) can be established via traditional bracketing approaches or in silico.…”
Section: Session 2: Basics and Best Practices On Dissolution Testingmentioning
confidence: 99%